CLDN10 Antibody

What is CLDN10 and what are its key characteristics?

CLDN10 (Claudin 10) is a tight junction protein in humans that may also be known as CPETRL3, HELIX, OSP-L, OSPL, OSP-like protein, and oligodendrocyte-specific protein-like. Structurally, it is a 24.5 kilodalton protein that plays a crucial role in cell-to-cell adhesion and paracellular barrier functions . CLDN10 is strongly expressed in the thick ascending limb (TAL) of Henle's loop and weakly observed in the proximal tubule of the nephron . Understanding CLDN10's tissue-specific expression patterns is essential for designing experiments and interpreting immunostaining results in various tissue samples.

What types of CLDN10 antibodies are available for research applications?

Research-grade CLDN10 antibodies are available in several formats including monoclonal and polyclonal variants with various host species (rat, rabbit, mouse). Currently, there are at least 199 CLDN10 antibodies from 19 different suppliers with applications including Western Blot (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF), and Immunoprecipitation (IP) . Monoclonal antibodies offer higher specificity, particularly important given cross-reactivity concerns with other claudin family members, while polyclonal antibodies may provide stronger signals through recognition of multiple epitopes.

How do CLDN10A and CLDN10B isoforms differ, and how can antibodies distinguish between them?

CLDN10 exists in at least two splice variants - CLDN10A and CLDN10B - which differ in their first exon but share identical C-terminal regions. Most commercial antibodies target the C-terminal region (e.g., AA region 210-224) and therefore cannot distinguish between these isoforms . For isoform-specific detection, researchers must employ antibodies specifically raised against the unique N-terminal sequences or utilize RNA-based methods such as isoform-specific RT-PCR. Alternatively, expression vectors for specific isoforms can be used in cellular models to study their functional differences.

What are the cross-reactivity concerns with CLDN10 antibodies?

A significant challenge in CLDN10 research is antibody cross-reactivity with other claudin family members. Validation studies have shown that many commercially available anti-CLDN10 polyclonal antibodies cross-react with related claudins, particularly CLDN2, CLDN8, and CLDN15 . For example, a commercial anti-CLDN10 polyclonal antibody (Affinity Biosciences, AF0133) demonstrated strong cross-reactivity with CLDN15 and weaker reactions with CLDN2, CLDN8, and other claudins . Such cross-reactivity can lead to misinterpretation of experimental results, highlighting the critical importance of antibody validation for claudin research.

What methods should researchers use to validate CLDN10 antibodies?

Researchers should employ multiple validation approaches:

• Overexpression systems: Transfect cells with vectors expressing CLDN10 and related claudins (CLDN2, CLDN5, CLDN8, CLDN15) to test antibody specificity by immunohistochemistry and Western blotting .

• Knockout/knockdown controls: Use CLDN10 knockout or knockdown models as negative controls.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to confirm epitope specificity.

• Multiple detection methods: Compare results across different techniques (IHC, IF, WB).

• Tissue expression profiling: Verify that staining patterns match known CLDN10 expression profiles in tissues such as kidney (strong in TAL, weak in proximal tubule) .

What are the optimal conditions for Western blot detection of CLDN10?

For optimal Western blot detection of CLDN10:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitors for extraction; avoid boiling samples to prevent aggregation of this membrane protein.

• Gel conditions: Run on 12-15% SDS-PAGE to properly resolve the 24.5 kDa protein.

• Transfer parameters: Use semi-dry transfer with PVDF membranes (0.2 μm pore size) at 15V for 30-45 minutes.

• Blocking: 5% non-fat dry milk in TBST is generally effective.

• Antibody dilution: Optimal dilutions vary by product (typically 1:500 to 1:2000); titration is recommended.

• Detection method: HRP-conjugated secondary antibodies with ECL detection provide good sensitivity.

• Controls: Include positive controls (kidney tissue lysates) and negative controls (tissues known not to express CLDN10).

For membrane proteins like CLDN10, careful attention to sample preparation is critical to prevent aggregation and maintain epitope accessibility.

What are the key considerations for immunohistochemical detection of CLDN10?

For successful immunohistochemical detection of CLDN10:

• Fixation: 10% neutral buffered formalin fixation for 24-48 hours is standard.

• Antigen retrieval: Citrate buffer (pH 5.0) retrieval using microwave heating is effective .

• Blocking: Use avidin/biotin blocking kit followed by 0.5% casein to minimize background .

• Antibody incubation: Overnight incubation at 4°C with primary antibody provides optimal results.

• Signal amplification: For formalin-fixed tissues, signal amplification with biotinyl tyramide (1.5 nM) followed by HRP-conjugated streptavidin can significantly improve sensitivity .

• Controls: Include known positive tissues (kidney TAL segments) and negative controls (primary antibody omission).

• Counterstain: Light hematoxylin counterstaining maintains visibility of membrane staining.

How can CLDN10 antibodies be used for co-immunoprecipitation studies?

For co-immunoprecipitation of CLDN10 and its binding partners:

• Lysis conditions: Use mild lysis buffers (1% NP-40 or 1% Triton X-100 with 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) to preserve protein-protein interactions.

• Pre-clearing: Pre-clear lysates with protein G beads to reduce non-specific binding.

• Antibody binding: Incubate 1-5 μg of anti-CLDN10 antibody with 500-1000 μg of pre-cleared lysate overnight at 4°C.

• Precipitation: Add protein G beads and incubate for 2-4 hours at 4°C with gentle rotation.

• Washing: Use at least 4-5 washes with lysis buffer to remove non-specific interactions.

• Elution: Elute complexes with SDS sample buffer for downstream analysis.

• Controls: Include IgG control immunoprecipitations and input samples.

This approach has successfully identified novel CLDN10 binding partners, including LAT1 (L-type amino acid transporter 1), revealing important functional interactions in cancer cells .

What is known about CLDN10 expression in renal cell carcinoma and its prognostic value?

Recent research has established CLDN10 as a significant prognostic marker in clear cell renal cell carcinoma (ccRCC). High CLDN10 expression predicts poor outcome in ccRCC patients and represents an independent prognostic marker for cancer-specific survival . Interestingly, this finding contradicts earlier studies based on gene expression databases that suggested reduced CLDN10 expression correlates with poor prognosis in RCC . This discrepancy highlights the importance of using validated, specific antibodies for protein-level analysis, as earlier studies may have relied on cross-reactive antibodies or mRNA levels that don't necessarily correlate with protein expression.

How does CLDN10 interact with other proteins to influence cancer progression?

CLDN10 forms a complex with LAT1 (L-type amino acid transporter 1) in ccRCC cells, as demonstrated through immunoprecipitation-mass spectrometry and confirmed by co-immunoprecipitation studies . This interaction likely occurs between the transmembrane domain 1 (TM1) of CLDN10 and transmembrane domain 4 (TM4) of LAT1. The CLDN10-LAT1 complex activates mTOR signaling and expression of downstream targets, including MYC target genes, ultimately promoting malignant phenotypes including enhanced cell viability, proliferation, migration, and tumor growth in ccRCC . This represents a novel extrajunctional function of CLDN10 distinct from its classical role in tight junctions.

What methodological approaches can distinguish between junctional and extrajunctional CLDN10?

Differentiating junctional from extrajunctional CLDN10 requires specialized techniques:

• High-resolution confocal microscopy: Co-staining with other tight junction markers (ZO-1, occludin) can identify co-localization at cell-cell contacts (junctional) versus diffuse membrane distribution (extrajunctional).

• Cell surface biotinylation: Selectively labels extracellular domains of membrane proteins, allowing quantification of surface-exposed CLDN10.

• Subcellular fractionation: Separation of tight junction-enriched fractions from other membrane compartments, followed by Western blotting.

• Electron microscopy with immunogold labeling: Provides ultrastructural localization of CLDN10.

• Detergent solubility assays: Junctional CLDN10 is typically more detergent-resistant than extrajunctional pools.

These approaches have revealed that CLDN10 in cancer cells often localizes outside of tight junctions, where it can interact with partners like LAT1 to promote signaling functions distinct from barrier regulation .

How can researchers effectively study the functional impact of CLDN10 in cellular models?

To study CLDN10 function in cellular models:

• Overexpression systems: Transfect cells with CLDN10 expression vectors to study gain-of-function effects. Both isoforms (CLDN10A and CLDN10B) should be tested independently.

• CRISPR/Cas9 knockout: Generate CLDN10-null cell lines to study loss-of-function effects.

• siRNA/shRNA knockdown: For transient or stable reduction of CLDN10 expression.

• Site-directed mutagenesis: Introduce specific mutations to study structure-function relationships, particularly in transmembrane domains implicated in protein-protein interactions.

• Inducible expression systems: Use doxycycline-inducible promoters to control the timing and level of CLDN10 expression.

• Reporter assays: Couple CLDN10 expression to downstream signaling readouts (e.g., mTOR activity reporters).

• Live-cell imaging: Use fluorescently tagged CLDN10 to monitor subcellular localization and dynamics.

These approaches have been successfully employed to demonstrate that cell surface CLDN10 promotes cell viability, proliferation, and migration of ccRCC cells, as well as tumor growth in vivo .

What are the most appropriate animal models for studying CLDN10 function?

For in vivo CLDN10 research:

• Conditional knockout models: Tissue-specific Cre-loxP systems allow deletion of CLDN10 in specific cell types (e.g., renal tubule cells) while avoiding embryonic lethality.

• Xenograft models: Implantation of CLDN10-manipulated human cancer cells into immunodeficient mice to study tumor growth and metastasis.

• Patient-derived xenografts (PDX): Maintain tumor heterogeneity while allowing manipulation of CLDN10 pathways.

• CRISPR-engineered models: Introduction of specific CLDN10 mutations to study variant effects.

• Orthotopic models: Implantation of cells directly into the organ of origin (e.g., kidney for ccRCC studies) to maintain appropriate microenvironment.

When designing animal studies, researchers should consider species differences in CLDN10 expression patterns and potential compensatory mechanisms through other claudin family members.

What methodological approaches can identify novel CLDN10 binding partners?

Several complementary approaches can identify CLDN10-interacting proteins:

• Immunoprecipitation-mass spectrometry (IP-MS): The gold standard for unbiased identification of protein complexes. This approach successfully identified LAT1 as a CLDN10 binding partner .

• Proximity labeling: BioID or APEX2 fused to CLDN10 to biotinylate proximal proteins, followed by streptavidin pulldown and MS analysis.

• Yeast two-hybrid screening: Useful for identifying direct binary interactions.

• Protein complementation assays: Split luciferase or GFP systems to validate interactions in living cells.

• Co-immunoprecipitation with candidate proteins: Targeted approach based on hypothesized interactions.

• Cross-linking mass spectrometry: Identifies interaction interfaces between CLDN10 and binding partners.

• In silico structural prediction: Computational approaches can predict potential interaction domains, as demonstrated for CLDN10-TM1 and LAT1-TM4 .

How can researchers address weak or absent CLDN10 signal in Western blots?

When facing weak or absent CLDN10 signals in Western blots:

• Sample preparation optimization:

  • Use specialized membrane protein extraction buffers

  • Avoid sample boiling (heat to 37°C instead)

  • Increase protein concentration (50-100 μg per lane)

• Transfer optimization:

  • Use PVDF rather than nitrocellulose membranes

  • Extend transfer time for membrane proteins

  • Add SDS (0.1%) to transfer buffer to improve elution

• Detection enhancement:

  • Try signal amplification systems (e.g., SuperSignal West Femto)

  • Increase primary antibody concentration and incubation time

  • Use high-sensitivity film or longer exposure times with digital systems

• Antibody selection:

  • Test multiple antibodies recognizing different epitopes

  • Consider using antibodies specifically validated for Western blotting

• Positive controls:

  • Include known CLDN10-expressing tissues (kidney) as positive controls

What strategies can overcome non-specific binding in immunohistochemistry?

To reduce non-specific binding in CLDN10 immunohistochemistry:

• Blocking optimization:

  • Use species-matched serum (5-10%)

  • Try protein-free blocking reagents

  • Consider avidin/biotin blocking for biotin-based detection systems

  • Use 0.5% casein as an alternative blocking agent

• Antibody optimization:

  • Titrate primary antibody concentration

  • Reduce incubation temperature (4°C overnight instead of room temperature)

  • Use monoclonal antibodies for higher specificity

• Washing optimization:

  • Increase wash steps (5-6 times)

  • Use higher detergent concentration (0.1-0.3% Tween-20)

  • Extend wash durations (10 minutes per wash)

• Antigen retrieval optimization:

  • Compare different pH buffers (citrate pH 5.0 vs. pH 6.0 vs. EDTA pH.9.0)

  • Test different retrieval methods (microwave, pressure cooker, water bath)

• Controls:

  • Include absorption controls with immunizing peptide

  • Use tissues known to be negative for CLDN10

How can researchers accurately quantify CLDN10 expression in tissues and cells?

For accurate quantification of CLDN10 expression:

• Immunohistochemistry quantification:

  • Use digital image analysis software with consistent threshold settings

  • Employ H-score method (intensity × percentage of positive cells)

  • Consider automated systems with machine learning algorithms

  • Always include calibration controls in each batch

• Western blot quantification:

  • Use internal loading controls (β-actin, GAPDH)

  • Create standard curves with recombinant protein

  • Employ fluorescent secondary antibodies for wider linear range

  • Use digital image acquisition and analysis software

• Flow cytometry:

  • Optimize permeabilization for intracellular epitopes

  • Use median fluorescence intensity (MFI) for quantification

  • Include isotype controls and compensation

• qPCR considerations:

  • Design primers specific to CLDN10 isoforms

  • Use multiple reference genes for normalization

  • Create standard curves to ensure linear amplification

• Tissue microarrays:

  • Use standardized scoring systems and multiple cores per sample

  • Implement blinded assessment by multiple pathologists

What emerging technologies might improve CLDN10 detection and functional analysis?

Several emerging technologies show promise for advancing CLDN10 research:

• Super-resolution microscopy techniques (STORM, PALM, SIM) for nanoscale localization of CLDN10 within tight junctions and other membrane domains.

• Single-cell proteomics to resolve CLDN10 expression heterogeneity within tissues and tumors.

• Nanobodies and single-domain antibodies offering improved penetration into tight junction complexes and potential for intrabody applications.

• CRISPR activation/interference (CRISPRa/CRISPRi) for precise modulation of endogenous CLDN10 expression.

• Antibody-drug conjugates targeting CLDN10 in cancer therapy, particularly for tumors with aberrant CLDN10 overexpression like ccRCC.

• Spatial transcriptomics and proteomics to map CLDN10 expression patterns in relation to tissue architecture and microenvironment.

• Organoid models with engineered CLDN10 variants to study functional effects in physiologically relevant 3D systems.

How can researchers address contradictory findings about CLDN10 expression in cancer?

To reconcile contradictory findings regarding CLDN10 in cancer:

• Antibody validation is critical: Many contradictions stem from antibody cross-reactivity, as demonstrated by the discrepancy between studies using specific monoclonal antibodies versus cross-reactive polyclonal antibodies .

• Distinguish mRNA from protein: Transcriptomic studies may show different patterns than proteomic/immunohistochemical studies; both should be performed in parallel.

• Consider isoform-specific effects: CLDN10A and CLDN10B may have different or even opposing functions.

• Account for subcellular localization: Junctional versus extrajunctional CLDN10 may have distinct functional implications.

• Evaluate cancer subtypes separately: Different molecular subtypes within the same cancer type may show opposite CLDN10 expression patterns.

• Temporal dynamics: CLDN10 expression may change during disease progression, with different implications for early versus late-stage disease.

• Methodology standardization: Adopt standardized protocols for tissue processing, antibody validation, and quantification.

What considerations should guide the development of next-generation CLDN10 antibodies?

For development of improved CLDN10 antibodies:

• Isoform specificity: Design antibodies against unique N-terminal regions to distinguish CLDN10A from CLDN10B.

• Conformation-specific antibodies: Develop antibodies that recognize specific conformational states of CLDN10.

• Application optimization: Engineer antibodies specifically optimized for particular applications (IHC, IF, WB, IP) rather than general-purpose reagents.

• Functional antibodies: Create antibodies that can modulate CLDN10 function (activating or blocking) for potential therapeutic applications.

• Species cross-reactivity: Ensure recognition of orthologous proteins across experimental model species.

• Recombinant antibody technology: Utilize recombinant production for improved batch-to-batch consistency.

• Validation package: Develop comprehensive validation data packages including knockout controls, peptide competition assays, and cross-reactivity panels with related claudins.